Product Information
MEXILETINE 250 MG CAPSULE is a generic product labeled by Ingenus Pharmaceuticals LLC, priced at $0.3872 per EA under NDC 50742024101. Its NADAC has been published 231 times since Jun 2, 2021.
FDA first approved this application on Jan 25, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Ingenus Pharmaceuticals LLCNDC
50742024101
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEXILETINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA214352FDA Approved
1/25/2021
TE Code
AB
On Market Since
1/26/2021
Pharmacological Classes
Price Statistics
The NADAC for MEXILETINE 250 MG CAPSULE has been published 231 times since Jun 2, 2021, and over the history we have for it it has declined 74.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3872 per EA |
|---|---|
| All-time high | $1.4878 (Jan 12, 2022) |
| All-time low | $0.3872 (Sep 23, 2026) |
| 52-week high | $0.4943 |
| 52-week low | $0.3872 |
| Median price | $0.4814 |
| Average price | $0.7772 |
| Largest weekly change | -57.2% (Apr 17, 2024) |
| Weeks tracked | 231 |
| Tracking since | Jun 2, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ingenus Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mexiletine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEXILETINE 250 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MEXILETINE 250 MG CAPSULE, manufactured by Ingenus Pharmaceuticals LLC, is $0.3872 per EA (NDC 50742024101), effective Sep 30, 2026.
How has the price of MEXILETINE 250 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MEXILETINE 250 MG CAPSULE has declined 74.0%. It has been tracked across 231 weekly CMS publications since Jun 2, 2021.
What are the highest and lowest recorded NADAC prices for MEXILETINE 250 MG CAPSULE?
Since Jun 2, 2021, the NADAC for MEXILETINE 250 MG CAPSULE has ranged from a low of $0.3872 (Sep 23, 2026) to a high of $1.4878 (Jan 12, 2022), with a median of $0.4814 per EA.
Are there cheaper alternatives to MEXILETINE 250 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as MEXILETINE 250 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures MEXILETINE 250 MG CAPSULE?
MEXILETINE 250 MG CAPSULE (NDC 50742024101) is labeled by Ingenus Pharmaceuticals LLC, and CMS classifies it as a generic product.